Tag Archives: transcatheter aortic valve implantation

2 Encuentro Educativo ProEducar | Implante de Válvula Aórtica

2° ProEducar Educational Meeting – Aortic Valve Implantation. Session II

2° ProEducar Educational Meeting – Aortic Valve Implantation. Session II

Watch again our “2nd ProEducar Educational Meeting on “Transcatheter Aortic Valve Implantation” on our Youtube account.  We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.


New Self-Expanding Valve Measures Up Against Sapien 3

Both balloon-expandable and self-expanding valves have been tested in randomized studies, with excellent outcomes. While both technologies have advantages, the chance to reposition or re-steer the sheath is only offered by self-expanding valves, which also adjust better to patient anatomy. The CHOICE trial, published in 2014 in JAMA, was one of the few randomized studies

valve in valve

VIVA Post-Market Study: More Evidence for the Valve-in-Valve Technique

Courtesy of the SBHCI. Bioprosthetic surgically-implanted valves degenerate over time, while patients become too old and are at high risk for reoperation.   Transcatheter aortic valve implantation inside a deteriorated surgically-implanted valve (a valve-in-valve procedure) is an emerging alternative.   The VIVA trial was designed to offer systematic and prospective data from patients treated with

La protección cerebral en TAVI continúa con evidencia débil pero con esperanzas

Cerebral protection during TAVI still offers weak evidence, but there is hope

Silent ischemic embolic lesions are common after transcatheter aortic valve implantation (TAVI). The use of cerebral protection devices might reduce the occurrence of these embolic lesions. Multiple studies with different devices, designs, and outcomes challenge the usefulness of cerebral protection during TAVI.   A comprehensive analysis of the literature was necessary to obtain a more


REPRISE III: Lotus and CoreValve Compared in High-Risk or Inoperable Patients

The efficacy of transcatheter aortic valve replacement (TAVR) has been well-established. However, its limitations include suboptimal deployment and paravalvular leak. The Lotus system is a fully repositionable and retrievable device with controlled mechanical expansion. It features an adaptive seal to minimize paravalvular leak, it does not require early pacing during deployment, and, given its early

Más evidencia positiva para tratar prótesis biológicas disfuncionantes con la prótesis balón expandible

Further Evidence on Managing Dysfunctioning Bioprostheses with Balloon-Expandable Prostheses

Early experience with the valve-in-valve technique in the treatment of failed bioprosthetic surgical valves in transcatheter aortic valve replacement (TAVR) has yielded acceptable acute procedural results. This turned the technique into another therapeutic option, one that could even cause the reassessment of the age limit for the surgical implantation of a mechanical or bioprosthesis valve.

Post TAVI pacemaker implantation does not increase mortality

Original Title: Impact of New-Onset Left Bundle Branch Block and Periprocedural Permanent Pacemaker Implantation on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. A Systematic Review and Meta-Analysis. Reference: Ander Regueiro et al. Circ Cardiovasc Interv. 2016 May;9(5).   Available data on the clinical impact of the new-onset left bundle branch block (LBBB) and


TriGuard: NeuroProtection Device during TAVI

Original Title: A Patient Level Pooled Analysis of NeuroProtection with the TriGuard Embolic DEFLECTion Device Compared to Unprotected Transcatheter Aortic Valve Replacement. Presenter: Alexandra Lansky   This work was designed to assess the safety and efficacy of the TriGuard device as a complement during transcatheter aortic valve implantation (TAVI) compared to no protection in a

Arne Schwindt

FRONTIER II: One Year Outcomes of the New Vascular Closure Device

Original Title: 12-month results of a novel large access closure device: insights from the FRONTIER II Study. Presenter: Arne Schwindt   The FRONTIER II trial assessed the safety and efficacy of the vessel closure device VIVASURE in more than 50 patients using the femoral access for TAVI or aortic endoprosthesis. Puncture site was assessed at